Innovative lead Montis Biosciences is a preclinical-stage biopharma focusing on inflammation-driven autoimmune and neurodegenerative disorders, presenting a potential opportunity to partner on early-stage asset discovery, technology collaboration, and co-development strategies.

C1q platform Lead program MB01 targets C1q with novel antibodies that modulate complement-independent functions, offering a distinctive differentiator for collaboration with companies seeking next-generation complement therapies or neuroinflammation solutions.

MB02 oncology Second program MB02 targets CD93 in lung squamous cell carcinoma with best-in-class potential, signaling a potential licensing or strategic partnership around perivascular macrophage interactions and inflammatory oncology.

Clinical momentum Plans to initiate two Phase 1 trials in 1H 2026 indicate upcoming clinical milestones that can attract early partnering discussions, co-development deals, or milestone-driven investments.

Strategic backing Strong investor syndicate and previous VLAIO funding plus a compact team profile suggest low-capital ceiling for early-stage collaborations with ASOs/biologics manufacturers, CROs, and contract development partners seeking early-stage innovators.